{"id":"W2568354557","doi":"10.1182/blood.v108.11.3536.3536","title":"A Phase I-II Trial of Bortezomib Plus Oral Cyclophosphamide and Prednisone for Relapsed/Refractory Multiple Myeloma.","year":2006,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Neutropenia; Bortezomib; Internal medicine; Gastroenterology; Multiple myeloma; Cyclophosphamide; Lenalidomide; Thalidomide; Toxicity; Febrile neutropenia; Refractory (planetary science); Urology; Surgery; Chemotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00156219,0.001712608,0.001648649,0.0004574164,0.0005068217,0.0007680309,0.0007791574,0.0008789418,0.005195501],"category_scores_gemma":[0.0006351219,0.0006297835,0.001039079,0.0003805557,0.0008332427,0.0004951075,0.000318163,0.003323723,0.001118696],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007990623,"about_ca_system_score_gemma":0.001251975,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001383834,"about_ca_topic_score_gemma":0.002987494,"domain_scores_codex":[0.9996305,0.000202982,0.00001717326,0.00004957702,0.00002771183,0.0000720243],"domain_scores_gemma":[0.9995036,0.00006881899,0.00007088749,0.00002796628,0.00002209007,0.0003066374],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.8711538,0.03525219,0.002928666,0.0006972283,0.0009226725,0.0003079235,0.0001133848,0.001199977,0.02154133,0.000228225,0.005899694,0.05975494],"study_design_scores_gemma":[0.841481,0.1505413,0.004202999,0.00003253505,0.0002189692,0.0001254701,0.00001988687,0.0005411156,0.001105758,0.0001090696,0.001612895,0.000009028903],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9808049,0.004898636,0.0007172881,0.001399007,0.000603185,0.005688949,0.001486364,0.000199195,0.004202624],"genre_scores_gemma":[0.9792178,0.003002832,0.001889993,0.001906579,0.0005320226,0.004371977,0.003589615,0.00003574511,0.005453396],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005195501,"threshold_uncertainty_score":0.01738065,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02489002344502734,"score_gpt":0.3103489872472944,"score_spread":0.285458963802267,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}